文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌

2024年WHO细菌优先病原体清单:指导抗菌药物耐药性研究、开发与公共卫生策略的优先排序研究

The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance.
PubMed 文献 · Lancet Infect Dis · 2025-04-14

2024年WHO细菌优先病原体清单采用多标准决策分析框架,对24种抗生素耐药细菌基于八项标准评分,并通过100名国际专家的偏好调查确定权重。最终排名中碳青霉烯耐药肺炎克雷伯菌总分最高(84%),青霉素耐药B组链球菌最低(28%);革兰阴性菌和利福平耐药结核分枝杆菌仍为最高优先级。该清单旨在指导全球抗菌药物耐药性防控的研究投入和公共卫生政策。

要点

  • 碳青霉烯耐药肺炎克雷伯菌总分84%居首,青霉素耐药B组链球菌28%居末。
  • 革兰阴性菌(肺炎克雷伯菌、不动杆菌属、大肠埃希菌)和利福平耐药结核分枝杆菌列入最高四分位。
  • 社区获得性感染中,氟喹诺酮耐药伤寒沙门菌血清型Typhi(72%)、志贺菌属(70%)、淋病奈瑟菌(64%)排名较高。

核心结论

  • 2024年WHO细菌优先病原体清单是优先研究开发投入和指导全球公共卫生政策以应对抗菌药物耐药性的关键工具。
  • 革兰阴性菌和利福平耐药结核分枝杆菌仍是最高优先级病原体,凸显其持续威胁和当前抗菌药物研发管线的局限性。
  • 需要针对抗菌药物耐药优先病原体开展集中努力和持续投资,包括高负担的耐药细菌如沙门菌属、志贺菌属、淋病奈瑟菌和金黄色葡萄球菌。
  • 除研究开发外,应对这些病原体的努力还应包括扩大现有药物的公平可及性、提高疫苗覆盖率和加强感染预防与控制措施。

研究设计与样本

  • 2024年WHO细菌优先病原体清单由WHO抗菌药物耐药性部门通过奥地利政府、德国政府、沙特阿拉伯政府和欧盟委员会健康紧急准备与响应局的资助开展。
  • 采用多标准决策分析框架,对24种抗生素耐药细菌基于八项标准评分:死亡率、非致死性负担、发病率、10年耐药趋势、可预防性、传播性、可治疗性和抗菌药物研发管线状态。
  • 通过 pairwise 比较对100名国际专家进行偏好调查(79人回复,78人完成调查),以确定标准的相对权重。
  • 对每种病原体计算0-100%范围的总分以确定最终排名,并进行亚组和敏感性分析评估专家一致性、背景和地理来源对排名稳定性的影响。
  • 独立咨询组审查最终清单,病原体基于四分位评分系统简化和分组为三个优先层级:最高优先级(最高四分位)、高优先级(中间四分位)和中优先级(最低四分位)。

主要发现

  • 病原体总分范围从排名最高的细菌碳青霉烯耐药肺炎克雷伯菌的84%到排名最低的细菌青霉素耐药B组链球菌的28%。
  • 抗生素耐药革兰阴性菌(包括肺炎克雷伯菌、不动杆菌属和大肠埃希菌)以及利福平耐药结核分枝杆菌被列入最高四分位。
  • 在常见社区获得性感染细菌中,排名最高的是氟喹诺酮耐药伤寒沙门菌血清型Typhi(72%)、志贺菌属(70%)和淋病奈瑟菌(64%)。
  • 清单中其他重要病原体包括铜绿假单胞菌和金黄色葡萄球菌。
  • 偏好调查结果显示评分者间高度一致,Spearman等级相关系数和Kendall一致性系数均为0.9;最终排名显示高稳定性,基于专家背景和来源的病原体聚类未导致排名实质性变化。

关键数值与推荐

  • 碳青霉烯耐药肺炎克雷伯菌总分84%,排名最高。
  • 青霉素耐药B组链球菌总分28%,排名最低。
  • 氟喹诺酮耐药伤寒沙门菌血清型Typhi总分72%。
  • 志贺菌属总分70%。
  • 淋病奈瑟菌总分64%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2017 WHO Bacterial Priority Pathogens List (BPPL) has been instrumental in guiding global policy, research and development, and investments to address the most urgent threats from antibiotic-resistant pathogens, and it is a key public health tool for the prevention and control of antimicrobial resistance (AMR). Since its release, at least 13 new antibiotics targeting bacterial priority pathogens have been approved. The 2024 WHO BPPL aims to refine and build on the previous list by incorporating new data and evidence, addressing previous limitations, and improving pathogen prioritisation to better guide global efforts in combating AMR. METHODS: The 2024 WHO BPPL followed a similar approach to the first prioritisation exercise, using a multicriteria decision analysis framework. 24 antibiotic-resistant bacterial pathogens were scored based on eight criteria, including mortality, non-fatal burden, incidence, 10-year resistance trends, preventability, transmissibility, treatability, and antibacterial pipeline status. Pathogens were assessed on each of the criteria on the basis of available evidence and expert judgement. A preferences survey using a pairwise comparison was administered to 100 international experts (among whom 79 responded and 78 completed the survey) to determine the relative weights of the criteria. Applying these weights, the final ranking of pathogens was determined by calculating a total score in the range of 0-100% for each pathogen. Subgroup and sensitivity analyses were conducted to assess the impact of experts' consistency, background, and geographical origin on the stability of the rankings. An independent advisory group reviewed the final list, and pathogens were subsequently streamlined and grouped into three priority tiers based on a quartile scoring system: critical (highest quartile), high (middle quartiles), and medium (lowest quartile). FINDINGS: The pathogens' total scores ranged from 84% for the top-ranked bacterium (carbapenem-resistant Klebsiella pneumoniae) to 28% for the bottom-ranked bacterium (penicillin-resistant group B streptococci). Antibiotic-resistant Gram-negative bacteria (including K pneumoniae, Acinetobacter spp, and Escherichia coli), as well as rifampicin-resistant Mycobacterium tuberculosis, were ranked in the highest quartile. Among the bacteria commonly responsible for community-acquired infections, the highest rankings were for fluoroquinolone-resistant Salmonella enterica serotype Typhi (72%), Shigella spp (70%), and Neisseria gonorrhoeae (64%). Other important pathogens on the list include Pseudomonas aeruginosa and Staphylococcus aureus. The results of the preferences survey showed a strong inter-rater agreement, with Spearman's rank correlation coefficient and Kendall's coefficient of concordance both at 0·9. The final ranking showed high stability, with clustering of the pathogens based on experts' backgrounds and origins not resulting in any substantial changes to the ranking. INTERPRETATION: The 2024 WHO BPPL is a key tool for prioritising research and development investments and informing global public health policies to combat AMR. Gram-negative bacteria and rifampicin-resistant M tuberculosis remain critical priority pathogens, underscoring their persistent threat and the limitations of the current antibacterial pipeline. Focused efforts and sustained investments in novel antibacterials are needed to address AMR priority pathogens, which include high-burden antibiotic-resistant bacteria such as Salmonella and Shigella spp, N gonorrhoeae, and S aureus. Beyond research and development, efforts to address these pathogens should also include expanding equitable access to existing drugs, enhancing vaccine coverage, and strengthening infection prevention and control measures. FUNDING: This work is based on the development of the 2024 WHO BPPL, which was conducted by the WHO AMR Division through grants from the Government of Austria, the Government of Germany, the Government of Saudi Arabia, and the European Commission's Health Emergency Preparedness and Response Authority. TRANSLATIONS: For the Arabic, French, Italian, Japanese and Spanish translations of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sati H, Carrara E, Savoldi A, et al. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis. 2025. PMID: 40245910. doi:10.1016/S1473-3099(25)00118-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。